CHE| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Service Revenue and Sales | Beat | $673.30 million | $665.04 million (4 analysts) |
| Q2 Adjusted EPS | Beat | $6.06 | $5.60 (4 analysts) |
| Q2 EPS | $5.13 | ||
| Q2 Net Income | $67.70 million |
The current average analyst rating on the shares is "buy", with 1 strong buy or buy, 3 hold, and no sell or strong sell recommendations.
The median 12-month price target for Chemed Corp is $475.00, about 6.7% below its July 27 closing price of $509.34. The stock recently traded at 20 times next-12-month earnings, versus 15 three months ago.
VITAS patient growth helped revenue, mainly due to a 6.1% increase in days-of-care and a 9.0% rise in admissions.
A lower boosted VITAS revenue growth by .
Roto-Rooter commercial revenue rose 6.8%, led by plumbing and drain cleaning services.
Chemed said its second-quarter revenue rose 8.8%, beating analyst expectations, and adjusted earnings per share beat consensus, rising 41.9% year over year.
The company also repurchased 210,000 shares for $89.8 million in the quarter.
Chemed raised its full-year 2026 adjusted EPS guidance to $25.00-$25.75 from $24.00-$24.75.
It also lifted VITAS full-year ADC growth guidance to 5.75%-6.25% from 4.5%-5.5%. Roto-Rooter full-year revenue growth guidance was unchanged at 3.0%-3.5%.
